POET TECHNOLOGIES INC. (POET): Financial results for Q2 2026
POET TECHNOLOGIES INC. (POET) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 POET Technologies Reports Second Quarter 2026 Results: Revenue Up 112% Year-Over-Year in Sixth Consecutive Quarter of Sequential Growth Net loss narrows to ($0.07) per share; quarter-end cash and short-term investments of $796.3 million TORONTO, Aug. 13, 2026 (GLOBE
How this was made
The 30-second read
Why it matters
The earnings beat and financing strengthen the balance sheet, likely prompting a price uptick, but high R&D expenses warrant caution.
Market read
First‑hand earnings data for a niche AI‑hardware player; could influence sector sentiment and investor allocation to photonics stocks.
What to watch
Execution risk of scaling manufacturing and reliance on a few large customers.
Revenue Up 112% Year-Over-Year in Sixth Consecutive Quarter of Sequential Growth; net loss narrows to ($0.07) per share; quarter-end cash and short-term investments of $796.3 million.
Revenue grew 112% year over year and 13% sequentially, while the net loss narrowed sequentially and the Company completed a $400,000,020 financing. However, revenue remained $569,925, operating cash flow was ($12.2) million, research and development costs increased, and the outlook provided no quantitative financial guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenueother | 569,925 | 13% | 112% |
| Research and developmentother | (5,784,056) | – | – |
| Depreciation and amortizationother | (1,026,953) | – | – |
| Professional feesother | (725,691) | – | – |
| Wages and benefitsother | (2,778,119) | – | – |
| Stock-based compensationother | (3,816,906) | – | – |
| General expenses and rentother | (456,171) | – | – |
| Finance advisory feesother | (6,172,500) | – | – |
| Derivative liability adjustmentother | 5,531,784 | – | – |
| Interest expenseother | (67,894) | – | – |
| Other (income), including interestother | 4,299,496 | – | – |
| Unrealized foreign exchange (income) lossother | (910,975) | – | – |
| Net lossother | (11,338,060) | – | – |
| Net loss per share – Basic and Dilutedother | (0.07) | – | – |
| Cash flow from operating activitiesother | ($12.2) million | – | – |
| Cash and short-term investmentsother | $796.3 million | – | – |
the remaining quarters of 2026 outlook
- NoteThe Company expects to begin shipping substantial numbers of production units for qualification in the remaining quarters of 2026.
- NoteThe Company will make additional announcements and updates in September.
What drove it
- Revenue reflected non-recurring engineering (“NRE”) and product revenue of $569,925.
- The Company cited its sixth consecutive quarter of sequential revenue growth and an optical engine production ramp remaining on schedule for the second half of 2026.
- Lumilens placed an initial purchase order for manufacturing of POET Optical Interposer-based engines valued at $50 million.
- The Lumilens supplier relationship could scale to $500+ million in cumulative purchases from the Company over five years.
- The Company received a new purchase order for $2.4 million from an existing customer subsequent to quarter-end.
Concerns
- Revenue was $569,925 despite the reported year-over-year and sequential growth.
- Cash flow from operating activities was ($12.2) million.
- Research and development was ($5,784,056), compared with ($3,150,044) in the same period in 2025 and ($4,499,556) in the first quarter of 2026.
- The Company remains loss-making, reporting net loss of ($11,338,060).
- The production-unit shipping outlook is subject to prevailing confidentiality agreements and the risks described under “Cautionary Note Regarding Forward-Looking Information.”
- The Company cited risks including inability to deliver on existing purchase orders, changes in production requirements, timing and performance of capital equipment purchases, and component supply constraints.
What to watch
- Shipments of substantial numbers of production units for qualification in the remaining quarters of 2026.
- Additional Company announcements and updates in September.
- Execution of the Lumilens joint development program and the initial purchase order valued at $50 million.
- Commercialization and production-ramp progress associated with the collaboration with Lumilens.
- Delivery of the $2.4 million purchase order received subsequent to quarter-end.
- Expansion of manufacturing capacity in support of anticipated customer demand.
Balance sheet and cash flow
- The Company ended the quarter with $796.3 million in cash and short-term investments following completion of its $400 million financing in May.
- Cash flow from operating activities in the second quarter of 2026 was ($12.2) million compared to ($7.8) million in the second quarter of 2025 and ($8.8) million in the first quarter of 2026.
- Closed a registered direct offering by issuing 19,047,620 units at a price of $21 per unit for gross proceeds of $400,000,020.
- Each unit consisted of one common share and one common share purchase warrant, with each warrant being exercisable at a price of $26.25 until May 18, 2029.
Analysis
POET reported revenue of 569,925 for the second quarter ended June 30, 2026, up 112% from 268,469 in the second quarter of 2025 and 13% from 503,389 in the first quarter of 2026. Management characterized the result as its sixth consecutive quarter of sequential revenue growth. Revenue consisted of non-recurring engineering and product revenue, and the release did not provide revenue by operating segment, gross profit, or gross margin.
Net loss was (11,338,060), compared with (17,263,375) in the prior-year quarter and (12,344,086) in the first quarter. Net loss per share was (0.07), versus (0.21) and (0.08), respectively. The quarter included a 5,531,784 non-cash gain in the derivative liability adjustment, compared with a (7,559,991) non-cash loss a year earlier and a 1,602,298 gain in the first quarter. Other income, including interest, was 4,299,496.
Operating costs remained elevated as the Company described its transition from technology development to product development. Research and development was (5,784,056), up from (3,150,044) a year ago and (4,499,556) sequentially. Stock-based compensation was (3,816,906), finance advisory fees were (6,172,500), and cash flow from operating activities was ($12.2) million, compared with ($7.8) million in the prior-year quarter and ($8.8) million in the first quarter.
The balance sheet changed materially following the registered direct offering of 19,047,620 units at $21 per unit for gross proceeds of $400,000,020. The Company reported $796.3 million in cash and short-term investments at quarter-end. Each unit included one common share and one warrant exercisable at $26.25 until May 18, 2029. No repurchases or dividends were reported.
Commercial activity centered on the Lumilens relationship, including an initial purchase order valued at $50 million under a supply agreement that the Company said could scale to $500+ million in cumulative purchases over five years. Subsequent to quarter-end, POET received a $2.4 million purchase order from an existing customer and completed an agreement with a Tier 1 laser company to develop an external light source engine. Outlook was qualitative: the Company expects to begin shipping substantial numbers of production units for qualification in the remaining quarters of 2026 and plans further updates in September.
Management, verbatim
The second quarter showed POET’s transition from development to revenue taking hold: our sixth consecutive quarter of sequential revenue growth, a narrowing net loss, and our optical engine production ramp remaining on schedule for the second half of 2026.
Dr. Suresh Venkatesan, Chairman & CEO of POET Technologies
The $400 million strategic investment we completed in the quarter — priced at a premium to market — fundamentally strengthens POET’s financial position, removes the uncertainty associated with our staying power and enables management to focus entirely on executing our commercial and operational objectives.
Dr. Suresh Venkatesan, Chairman & CEO of POET Technologies
The appointment of Dr. Sandeep Kumar as Chief Operating Officer adds the operational and manufacturing leadership required as we scale our global operations.
Dr. Suresh Venkatesan, Chairman & CEO of POET Technologies
Not in the filing
stated, not guessed- Revenue by operating segment
- Gross profit
- Gross margin
- Total operating expenses
- Operating income or loss
- Income tax expense or benefit
- Tax rate
- Free cash flow
- Capital expenditures
- Debt
- Cash and short-term-investments comparisons with the prior-year quarter and prior quarter
- Quantitative revenue guidance
- Quantitative gross-margin guidance
- Quantitative operating-expense guidance
- Quantitative tax-rate guidance
- Prior outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
POET Technologies filed a Form 6‑K reporting its Q2 2026 results, including a $400M strategic financing and new supply agreements.
Ticker impact
Q2 2026 earnings show 112% YoY revenue growth and net loss narrowing to $0.07 per share.
Potential short‑term price rally as investors price in growth trajectory and cash runway.
Revenue surge and cash cushion reduce execution risk; market may re‑rate the stock.
Market effects
Highlights accelerating demand for photonic integrated circuits in AI/data‑center markets.
Boosts visibility of Canadian tech firms listed in the US.
Signals broader AI infrastructure spending trends.
Counterpoint
Rapid cash burn and high R&D spend could pressure margins if demand slows.
Key entities
- companyPOET Technologies Inc.
Photonic integrated circuits designer listed on NASDAQ (POET).
- partnerLumilens
Tier‑1 laser company entering a joint development and purchase agreement with POET.
